Abstract
Background
Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia.
Objectives
To identify variables that predict clozapine use after a first episode of schizophrenia (FES).
Methods
Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up during naturalistic treatment, and the patients who were initiated on clozapine were compared with those receiving non-clozapine antipsychotics for ≥24 months regarding demographic and clinical baseline characteristics, adherence, and relapse patterns during follow-up. Treatment-resistant schizophrenia was defined as two or more antipsychotic trials of adequate dose for ≥6 weeks.
Results
Twenty-eight patients who used clozapine and 77 non-clozapine antipsychotic users were included. Clozapine was initiated after a mean of 2.5 ± 1.1 adequate antipsychotic trials. Eight of the 28 clozapine-treated patients (28.6 %) began their clozapine treatment during the first 12 months of follow-up (mean 7.1 ± 3.3 months) and their premorbid childhood adjustment was significantly worse than those who started clozapine later (mean 78.5 ± 43.0 months). Compared with non-clozapine users, patients who started clozapine had significantly more relapses in the first 6 months of follow-up prior to clozapine use (35.7 vs. 11.7 %, p = 0.005), and were significantly more likely to have a first relapse despite treatment adherence (38.1 vs. 73.3 %, p = 0.01). In the multivariate analyses, antipsychotic polypharmacy and first relapse despite adherence to antipsychotic treatment independently predicted subsequent clozapine use.
Conclusions
Clozapine use after a FES was predicted by a first relapse while being adherent to non-clozapine antipsychotics, especially if the first relapse occurred within the first 6 months. Developmental childhood difficulties predicted significantly earlier clozapine use.
Similar content being viewed by others
References
Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialog Clin Neurosci. 2014;16:505–24.
Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751–62.
Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.
Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.
Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am. 2012;35:661–81.
Gören JL, Meterko M, Williams S, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv. 2013;64:527–33.
Harrison J, Janlov M, Wheeler AJ. Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm World Sci. 2010;32:503–11.
Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64:30–4.
Howes OD, Vergunst F, Gee S, Mcguire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201:481–5.
Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother. 2008;42:852–60.
Najim H, Heath D, Singh P. Antipsychotic prescribing before clozapine in a community psychiatric hospital: a case note review. Psychiatr Danub. 2013;25(Suppl 2):S165–70.
Wheeler AJ, Feetam CL, Harrison J. Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig. 2014;34:203–11.
Alessi-Severini S, Le Dorze JA, Nguyen D, et al. Clozapine prescribing in a Canadian outpatient population. PLoS One. 2013;8(12):e83539.
Paton C, Barnes TR, Cavanagh MR, POMH-UK Project team, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192:435–9.
Patel MX, Bishara D, Jayakumar S, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol. 2014;24(4):499–509.
Ucok A, Cikrikcili U, Karabulut S, et al. Delayed initiation of clozapine may be related with poor response in treatment-resistant schizophrenia. Int Clin Psychopharm. 2015;30:290–5.
Robinson DG, Schooler NR, John M, et al. Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry. 2015;172:237–48.
Huber G, Gross G, Schüttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6:592–605.
Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50(5):369–76.
Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544–9.
Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol. 2012;32:678–83.
Freudenreich O, McEvoy JP. Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects. Clin Schizophr Relat Psychoses. 2012;6:115–21.
Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–18.
Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72:1439–44.
Agid O, Schulze L, Arenovich T, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol. 2013;23:1017–22.
Girgis RR, Phillips MR, Li X, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011;199(4):281–8.
Molina V, Taboada D, Aragüés M, et al. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia. Schizophr Res. 2014;158(1–3):223–9.
Sanz-Fuentenebro J, Taboada D, Palomo T, et al. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophr Res. 2013;149(1–3):156–61.
Li D, Feng G, He L. Case–control study of association between the functional candidate gene ERBB3 and schizophrenia in Caucasian population. World J Biol Psychiatry. 2009;10(4 Pt 2):595–8.
Herceg M, Jukić V, Vidović D, et al. Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. Croat Med J. 2008;49(2):215–23.
Woerner MG, Robinson DG, Alvir JM, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003;160:1514–6.
Ucok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res. 2011;189:33–7.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., revised. Washington, DC: American Psychiatric Association; 2000.
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders (SCID-I), clinical version. Washington, DC: American Psychiatric Association; 1997.
Ucok A, Polat A, Çakır S, Genc A. One year outcome in first episode schizophrenia predictors of relapse. Eur Arch Psychiatry Clin Neurosci. 2006;256:37–43.
Ucok A, Soygur H. The guideline for treatment of schizophrenia. Ankara: Psychiatric Association of Turkey; 2010.
Ventura J, Green MF, Shaner A, Liberman R. Training and quality assurance with the Brief Psychiatric Rating Scale: “the driftbusters”. Int J Method Psychiatr Res. 1993;3:221–44.
Andreasen NC. The scale for the assessment of positive symptoms (SAPS). Iowa City: University of Iowa; 1984.
Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa; 1983.
Cannon-Spoor H, Potkin S, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:471–84.
Malla AK, Norman RMG, Machanda R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res. 2002;54:231–42.
Simonsen E, Friis S, Haahr U, et al. Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr Scand. 2007;116:54–61.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported by the Scientific Research Projects Coordination Unit of Istanbul University (Project No. BYP-2016-20507).
Conflict of interest
Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Alkermes, Forum, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Otsuka, Pfizer, ProPhase, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and Pfizer. He received grant support from Takeda. Alp Üçok, Ugur Çıkrıkçılı, Ceylan Ergül, Öznur Tabak, Ada Salaj, and Sercan Karabulut declare that they have no conflict of interest related to this study.
Ethical approval
The study protocol was approved by the Istanbul Faculty of Medicine Ethical Committee. All procedures were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
All patients gave written informed consent.
Rights and permissions
About this article
Cite this article
Üçok, A., Çıkrıkçılı, U., Ergül, C. et al. Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. CNS Drugs 30, 997–1006 (2016). https://doi.org/10.1007/s40263-016-0358-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-016-0358-z